Haptoglobin genotype and the iron hypothesis of atherosclerosis

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 17-18

  Viener, Hilla Lee ^a   Levy, Andrew P ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; FERRITIN; HAPTOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYDROXYL RADICAL; IRON; SUPEROXIDE; TRANSFERRIN;

AEROBIC METABOLISM; ATHEROSCLEROSIS; DIABETES MELLITUS; GENE LOCUS; GENOTYPE; HUMAN; IRON STORAGE; NONHUMAN; NOTE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BINDING;

CARDIOVASCULAR DISEASES; CAROTID STENOSIS; DIABETES MELLITUS; GENETIC PREDISPOSITION TO DISEASE; HAPTOGLOBINS; HEMOSIDERIN; HUMANS; HYPOGLYCEMIC AGENTS; IRON; OXIDATIVE STRESS; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79955532345     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.029     Document Type: Note

References (23)

1. Sullivan J.L. Iron and the sex difference in heart disease risk. Lancet 1981, 1:1293-1294.
2. Sullivan J.L. Iron in arterial plaque: a modifiable risk factor for atherosclerosis. Biochem Biophys Acta 2009, 1790:718-723.
3. Breuer W., Hersko C., Cabantchik Z.I. The importance of non transferring bound iron in disorders of iron and metabolism. Transfus Sci 2000, 23:185-192.
4. Breuer W., Shvartsman M., Cabantchik Z.I. Intracellular labile iron. Int J Biochem Cell Biol 2008, 40:350-354.
5. Asleh R., Guetta J., Kalet-Litman S., Miller-Lotan R., Levy A.P. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ Res 2005, 96:435-441.
6. Bowman B.H., Kurosky A., Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Gen 1982, 12:189-261.
7. Levy A.P., Asleh R., Blum S., et al. Haptoglobin: basic and clinical aspects. Antioxidant Redox Signal 2010, 12:293-304.
8. Blum S., Vardi M., Brown J.B., et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 2010, 11:675-759.
9. Levy A.P., Hochberg I., Jablonski K., et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Card 2002, 40:1984-1990.
10. RoguinA, Koch W., Kastrati A., et al. Haptoglobin genotype is predictive of major adverse cardiac events in the 1 year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 2003, 2628-2631.
11. Suleiman M., Aronson D., Asleh R., et al. Haptoglobin polymorphism predicts 30 day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005, 54:2802-2806.
12. Milmam U., Blum S., Shapira C., et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double blinded clinical trial. Arterioscler Thromb Vasc Biol 2008, 28:341-347.
13. Costacou T., Ferrell R.E., Orchard T.J. Haptoglobin genotype: a determinant of cardiovascular complication risk in type I diabetes. Diabetes 2008, 1702-1706.
14. Levy A.P., Levy J.E., Kalet-Litman S., et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007, 27:134-140.
15. Schwartz A., Blum S., Asleh R., Pollak M., Levy A.P. Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction. Pharmacogenomics Personal Med 2009, 2:1-8.
16. Asleh R., Marsh S., Shilkrut M., et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003, 92:1193-1200.
17. Asleh R., Blum S., Kalet-Litman S., et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008, 57:2794-2800.
18. Levy A.P., Moreno P.R. Intraplaque hemorrhage. Curr Mol Med 2006, 6:479-488.
19. Kalet-Litman S., Moreno P.R., Levy A.P. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis 2010, 209:28-31.
20. Moreno P., Puroshothaman K.R., Puroshothaman M., et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Card 2008, 52:1049-1051.
21. Lioupis C., Barbatis C., Drougou A., et al. Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis 2011, 216:131-138.
22. Levy A.P., Purosothaman K.R., Levy N.S., et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 2007, 101:106-110.
23. Nemeth E., Ganz T. Regulation of iron metabolism by hepcidin. Ann Rev Nut 2006, 26:323-342.